Multiplex HPV Detection via RPA and CRISPR-Cas12a
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV detection technologies face challenges such as complex instruments, cumbersome operations, high costs, and difficulty in multi-target detection, limiting their effectiveness and accessibility, especially in primary hospitals and clinics.
Innovation Solution
A kit and method combining multiplex recombinase polymerase amplification (RPA), CRISPR-Cas12a, and a microfluidic chip for rapid and low-cost detection and typing of HPV subtypes, using specifically designed RPA primers and crRNA sets, which allows for sensitive, precise, and high-throughput analysis without the need for expensive equipment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional HPV detection methods (PCR, hybrid capture) are used, then detection accuracy can be maintained, but device complexity and operational complexity increase significantly
Solution Approach 1:
The patent replaces complex mechanical instrumentation systems (PCR thermal cyclers, hybrid capture instruments) with a simplified isothermal amplification system using recombinase polymerase amplification (RPA) at constant temperature (37-42°C), eliminating the need for sophisticated temperature cycling equipment while maintaining detection accuracy through alternative biochemical mechanisms
Solution Approach 2:
The patent changes the fundamental operational parameter from temperature cycling (PCR) to isothermal conditions (RPA), and from signal amplification through multiple enzymatic steps (hybrid capture) to direct CRISPR-Cas12a cleavage activity, thereby simplifying the device requirements while preserving measurement precision
2Reliability
If traditional HPV detection methods are used, then detection capability is achieved, but operational complexity and cost increase
Solution Approach 1:
The patent implements a self-service detection system where the CRISPR-Cas12a enzyme automatically cleaves the fluorescent reporter molecule upon recognizing and binding to the amplified HPV DNA target sequence, eliminating the need for complex operational protocols, manual signal processing steps, or specialized technician expertise required by traditional methods
Solution Approach 2:
The patent performs preliminary action by pre-assembling the CRISPR-Cas12a ribonucleoprotein complex with guide RNA and fluorescent reporter molecules before the detection reaction, so that upon addition of the sample and RPA amplification, the system is already primed and ready for immediate specific recognition and signal generation without requiring complex real-time operational decisions
3Productivity
If conventional detection methods are used, then detection can be performed, but cost and time consumption increase
Solution Approach 1:
The patent achieves continuous useful action by performing RPA amplification and CRISPR-Cas12a detection in a continuous one-pot reaction without intermediate purification steps, sample transfers, or instrument reconfiguration, thereby reducing both time loss and operational overhead while increasing detection throughput through streamlined workflow
Solution Approach 2:
The patent merges the amplification step (RPA) and detection step (CRISPR-Cas12a) into a single integrated reaction system where the amplified DNA product is directly detected by the pre-loaded Cas12a complex in the same reaction well, eliminating separate operational phases and reducing overall detection time and resource consumption
4Adaptability or versatility
If multiplex detection is implemented using traditional methods, then multi-target detection capability is achieved, but device complexity and cost increase significantly
Solution Approach 1:
The patent achieves universality by using a single CRISPR-Cas12a enzyme system that can recognize and cleave multiple different fluorescent reporter molecules, each labeled with a unique sequence complementary to a specific HPV subtype guide RNA, thereby enabling multiplex detection of multiple HPV subtypes (16, 18, 31, 33, 45, 52, 58) using the same simplified device platform without increasing instrument complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables simple, rapid, and sensitive HPV subtype detection with low sample consumption, high analysis speed, and no requirement for expensive instruments, making it suitable for screening and diagnosis in various medical institutions, including primary hospitals and clinics, while improving sensitivity and specificity.
Implementation Method 1
multiplex clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 12a (Cas12a)
Implementation Method 2
multiplex recombinase polymerase amplification (RPA)
Data Source
AI summary
A multi-target nucleic acid detection kit for human papillomavirus (HPV) typing includes a recombinase polymerase amplification (RPA) primer set, an enzyme and a buffer system for Cas12a-crRNA, and a reporter molecule that displays a signal. In the detection method, a multi-channel microfluidic chip is used as a carrier, and RPA primers are designed for corresponding regions of different HPV subtypes to allow isothermal amplification. A crRNA set is designed for amplicons of different subtypes. The crRNA recognizes an HPV target in a sample, and then activates the CRISPR-Cas12a and cuts a reporter group to release a signal, thereby achieving accurate detection on HPV subtypes. The detection method shows a high sensitivity, a low cost, and easy operations, and is expected to be widely used in the screening of HPV infection.